Company intelligence / Profile preview

Seed Technology Companies

New York, New York, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Seed Therapeutics is a biotechnology company focused on harnessing the power of Targeted Protein Degradation (TPD) to develop treatments for previously undruggable targets. As a subsidiary of BeyondSpring, the company utilizes a proprietary platform to discover and develop molecular glues and proteolysis-targeting chimeras (PROTACs). Their pipeline primarily targets oncology, with emerging programs in neurodegeneration and infectious diseases. Seed Therapeutics aims to leverage its deep expertise in E3 ligase biology to create highly selective and potent small molecule degraders.

Therapeutic areas: Infectious DiseasesOncologyNeurology
Modalities: Small moleculeProteolysis-targeting chimera therapyMolecular glue therapy
Industry: Biotech

Partnerships

Eli Lilly and Company

Beyond the preview

Go deeper on Seed Technology Companies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seed Technology Companies.

Explore the full profile